Please ensure Javascript is enabled for purposes of website accessibility

Why Alzamend Neuro Stock Fell More Than 14% Today

By James Brumley – Jul 26, 2021 at 4:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors have been driving it lower for over a month now, but the stock just reached a curious price level.

What happened

Shares of biotechnology name Alzamend Neuro (ALZN 3.36%) were down on the order of 14.3% in Monday's trading, following through on Friday's intraday reversal of a big news-driven gain. With time to put that news into the proper context, investors still see the company's stock as being overvalued.

So what

Monday's sell-off is in sharp contrast to Friday's rally, which at one point carried shares up as much as 44% before peeling back to what was essentially breakeven. The initial surge was sparked by news that Alzamend Neuro's experimental Alzheimer's disease treatment AL002 didn't present any toxicological concerns in early-stage testing in mice.

Businessman trying to hold up a falling chart.

Image source: Getty Images.

It's an encouraging report, to be sure. But the actual efficacy of AL002 (which is a process rather than a drug itself) remains unknown due to the pre-clinical nature of the company's efforts. So the press release is leaving investors wanting for something meatier.

Now what

The sudden pullback can't come as too much of a surprise to current and prospective shareholders. The company went public on June 15, and while its first trade was 480% above its IPO price of $5, shares have fallen pretty steadily back to their current price near $5 ever since. Any hint of a rebound rally since then was quickly met with a move to even lower lows.

There's much to be gleaned from the persistent pullback leading up to today's rout, but chief among these clues is that most investors aren't buying into the hype linked to the public offering itself. There's a reason. Perhaps it's concern that the biotech was only raising funds here and now to cash in on the market's current receptiveness to risky start-ups.

Still, being reeled back to its IPO price makes it an interesting speculation -- for investors who can stomach such risk.

James Brumley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alzamend Neuro, Inc. Stock Quote
Alzamend Neuro, Inc.
ALZN
$1.23 (3.36%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.